BofA analyst Tazeen Ahmad raised the firm’s price target on Apellis (APLS) to $29 from $26 and keeps a Neutral rating on the shares ahead of Q3 earnings, stating that on the company’s call the firm will look for color on Empaveli’s kidney disease early launch metrics.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis announces new data from Phase 3 VALIANT study on EMPAVELI
- Hold Rating for Apellis Pharmaceuticals Amid Limited Growth Potential and Market Challenges
- Apellis upgraded to Overweight from Equal Weight at Wells Fargo
- Cautious Outlook on Apellis Pharmaceuticals Amid Market Challenges and Financial Constraints
- Buy Rating for Apellis Pharmaceuticals: Long-Term Growth Potential Amidst Current Challenges